Within the LS group, higher cancer risks were found for MLH1 and MSH2 carriers than for MSH6 carriers for any cancer, colorectal, stomach, small bowel, urothelial, and endometrial cancer (Fig. 2 and Table 2, Additional file 1: Figure S8). Here, MSH2 is linked to Leigh syndrome.